A deep understanding of immunology is essential for developing a successful new biologic therapy, whether the disease indication you're interested in directly targets the immune system or there's only an immune component secondary to the pathobiology
At minimum, due their protein-based nature, all biotherapeutics will be recognized by the immune system. Understanding these interactions and either leveraging or mitigating them is critical
Having 20+ years of immunology research experience specializing in immuno-oncology and autoimmune diseases, we can guide you through cell-based assay development to demonstrate efficacy and MOA, in vivo POC studies, and clinical indication selection.
We've worked on a plethora of programs targeting many different aspects of the immune system, including; CD8 T cell exhaustion & dysfunction in oncology, T-follicular helper cells, autoantibodies, B cell depletion, immune exclusion in tumors, T-helper cells, Tregs, innate cells (NK cells, macrophages, neutrophils, myeloid cells), T/NK cell engagers, and more. Our intimate knowledge of the inner workings of the immune system can help you elucidate your target biology and design a program that can successfully navigate the complicated nuances of immunobiology.
Even if the indication you're interested doesn't directly involve the immune system, biologic drugs are recognized by the immune system. For example, protein-based drugs are taken up by antigen-presenting cells and can activate T & B cells to produce anti-drug antibodies, which can neutralize the potency of your drug. Innate immune cells can be directly activated by antibody-like drugs containing an Fc domain, which can lead to undesired side effects like cytotoxicity, complement activation, and cytokine release.
You may think immunology can be ignored, but there's hardly a disease indication where the immune system will ignore what you're trying to do.